J. Goldman & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

J. Goldman & Co’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-94,500	Closed	-$2.02M	–	547
2025 Q3	$2.02M	Sell	94,500 -10,500	-10%	-$248K	0.05%	276
2025 Q2	$2.26M	Buy	+105,000	New	+$1.95M	0.05%	263
2022 Q3	–	Sell	-53,900	Closed	-$760K	–	378
2022 Q2	$760K	Buy	+53,900	New	+$1.01M	0.04%	260
2018 Q3	–	Sell	-104,000	Closed	-$1.59M	–	252
2018 Q2	$1.59M	Buy	+104,000	New	+$1.85M	0.08%	224

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

J. Goldman & Co's ACAD Position: Q3 2025 in Review

J. Goldman & Co sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 164,278 shares — an estimated $3.89M sold.

J. Goldman & Co first reported a position in ACAD in Q2 2018 and held it in 4 quarters. The position peaked at $3.54M in Q2 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

J. Goldman & Co reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
J. Goldman & Co sold 164,278 Acadia Pharmaceuticals shares in Q3 2025, an estimated $3.89M.
J. Goldman & Co first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 4 quarters.
J. Goldman & Co's Acadia Pharmaceuticals position peaked at $3.54M in Q2 2025.
334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.